<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23498">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064413</url>
  </required_header>
  <id_info>
    <org_study_id>17069</org_study_id>
    <nct_id>NCT02064413</nct_id>
  </id_info>
  <brief_title>Essure (Model ESS310) Placement Rate Study</brief_title>
  <official_title>A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and successful placement rate of Essure Model ESS310 device and any
      factors that may influence the successful placement rate of this device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Rate of successful bilateral placement of the ESS310 insert at first attempt in subjects who undergo attempted ESS310 placement</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful bilateral placement rate of the ESS310 insert at first attempt in all subjects who undergo hysteroscopy with the intent of having bilateral ESS310 placement</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of investigator questionnaire regarding ESS310 design and usability</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Potential aspects of the ESS310 design and usability that may impact bilateral placement rate at first attempt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of investigator questionnaire regarding potential factors predictive of failure to achieve bilateral placement of the ESS310 insert at first attempt</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hysteroscopy time to perform the procedure</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse device effects (ADE) as a measure of safety and tolerability</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse procedure-related events as a measure of safety and tolerability</measure>
    <time_frame>Day 1, 1 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>ESS310</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESS310 (BAY1454032)</intervention_name>
    <arm_group_label>ESS310</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females aged range 21 to 44 years

          -  Subjects seeking permanent contraception

          -  Subjects with body weight within range of 90-300 pounds (40 - 136 kilograms)

          -  Subjects for whom medical history indicates bilateral viable and patent fallopian
             tubes

          -  Subjects are able and willing to comply with the protocol required follow-up visits

          -  Subjects have fulfilled local requirements for counseling and consent to
             contraception and sterilization, including any required waiting periods

          -  Subjects provide written informed consent prior to enrolment

          -  Subjects who have sufficient mental capacity to understand the informed consent form
             (ICF), comply with the protocol requirements, and provide clinically relevant and
             reliable feedback regarding their experience implant and subsequent wearing of the
             device

          -  Subjects who agree that anonymized personal data will be made available to study
             Sponsor and requisite regional and international regulatory bodies

        Exclusion Criteria:

          -  Subjects suspected of being or confirmed pregnant

          -  Subjects post-partum or undergone pregnancy termination ≤6 weeks of scheduled insert
             placement

          -  Subjects who have known proximal tubal occlusion in either fallopian tube

          -  Subjects who have undergone fallopian tube sterilization procedure

          -  Subjects who have had total or partial salpingectomies

          -  Subjects diagnosed with tubal, endometrial, or myometrial pathology which may prevent
             fallopian tube ostia access

          -  Subjects diagnosed with unicornuate uterus

          -  Subjects diagnosed with active or currently being treated upper or lower pelvic
             infection

          -  Subjects with gynecologic malignancy

          -  Subjects who are currently taking corticosteroids

          -  Subjects with a known allergy to all contrast media available for use in HSG
             (Hysterosalpingogram)

          -  Subjects scheduled to undergo concomitant intrauterine procedures at the time of
             insert placement (e.g., endometrial ablation, fibroid resection by hysteroscopy,
             endometrial polypectomy). Intrauterine device removal is not considered a concomitant
             procedure.

          -  Subjects with any general health condition or systemic disease that may represent, in
             the opinion of the physician, a potential increased risk associated with device use
             or pregnancy

          -  Subjects with a close affiliation with the investigational site, e.g. closely related
             or affiliated with the investigator (such as dependent, employee or student of the
             investigational site, or sponsor's staff)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409-2793</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Birth control</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
